|1.||Kawashima, Y: 2 articles (01/2001 - 11/2000)|
|2.||Matsumoto, K: 2 articles (01/2001 - 11/2000)|
|3.||Iwazaki, S: 2 articles (01/2001 - 11/2000)|
|4.||Sunose, Y: 2 articles (01/2001 - 11/2000)|
|5.||Ohwada, S: 2 articles (01/2001 - 11/2000)|
|6.||Tsutsumi, H: 2 articles (01/2001 - 11/2000)|
|7.||Morishita, Y: 2 articles (01/2001 - 11/2000)|
|8.||Takeyoshi, I: 2 articles (01/2001 - 11/2000)|
01/01/2001 - "FR128998 ameliorates liver injury in extended liver resection with ischemia in dogs."
11/01/2000 - "FR128998 ameliorates liver injury after ischemia-reperfusion with extended liver resection in dogs."
01/01/2001 - "FR128998 provides a protective effect for liver parenchyma and sinusoidal endothelial cells during extended liver resection with ischemia."
|2.||Disseminated Intravascular Coagulation
06/13/1994 - "Effect of FR128998, a novel PAF receptor antagonist, on endotoxin-induced disseminated intravascular coagulation."
06/13/1994 - "This study aimed to evaluate the effect of FR128998, (1s,6s)-1-benzyl-10-(3-pyridyl-methyl)-7-thia-10-azaspiro [5,6]-dodecan-11-one 7,7-dioxide hydrochloride, a novel platelet activating factor (PAF) receptor antagonist, on endotoxin lipopolysaccharide-induced disseminated intravascular coagulation in rats. "
06/13/1994 - "In addition, FR128998 attenuated the increase in serum tumor necrosis factor (TNF) which appeared during the initial stage of disseminated intravascular coagulation. "
06/13/1994 - "The changes in coagulation parameters of disseminated intravascular coagulation, i.e., prolongation of activated partial thromboplastin time and elevated levels of fibrinogen/fibrin degradation products, were also prevented by the treatment with FR128998. "
|1.||Platelet Activating Factor
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Fibrinogen (Factor I)
|4.||Fibrin Fibrinogen Degradation Products